Abstracts

819 – Very Early Seroreversion Among Infants Exposed to HIV in the Context of Effective Maternal ART

Background Increasingly, women with HIV (WHIV) begin effective antiretroviral therapy (ART) prior to conception, resulting in long-term sustained viral suppression. This may lead to lower circulating anti-HIV antibody levels during pregnancy and subsequently reduced maternal HIV antibody transfer to the fetus in utero. The objective of this study was to determine time to seroreversion among…

838 – Basal Proviral Transcription and Immune Correlates in Well-Suppressed Youths With Perinatal HIV-1

Background Background In adults with HIV-1, persistent proviral transcription despite years of sustained virologic suppression (VS) reflects a pool of long-term transcriptionally competent proviruses that may be targets for ART-free remission and cure therapies. Whether transcriptionally active proviruses persist and affect the immune system in adolescents living with longstanding perinatal HIV-1 (AdWPH) is unknown. Methods…

843 – Safety and Pharmacokinetics of Combination VRC07-523LS, PGDM1400LS, and PGT.121.414.LS in Children

Background Broadly neutralizing monoclonal antibodies (bNAbs) suppress HIV RNA and may promote HIV remission. We evaluated safety and pharmacokinetics (PK) of intravenous VRC07-523LS, PGDM1400LS, and PGT.121.414.LS in children with HIV on suppressive antiretroviral treatment (ART). Methods Children eligible for the safety and PK phase of the Tatelo Plus / IMPAACT 2042 Study received ART from <7…

1080 – Age Differences in PrEP Continuation Among Female Sex Workers and Young Women in South Africa

Background HIV risk among cisgender women in South Africa is heterogeneous across subpopulations, with adolescent girls and young women (AGYW) and female sex workers (FSW) at disproportionately high risk of HIV acquisition. While PrEP is an effective HIV prevention intervention, its preventive impact in South Africa has been limited by interruptions in PrEP continuation and…

626 – Clinical Impact of Kaposi Sarcoma Herpesvirus Subtypes on Disease Outcomes

Background Kaposi sarcoma herpesvirus (KSHV), also known as human herpesvirus 8 (HHV-8), is an oncogenic DNA virus that causes several diseases in people with HIV (PWH), including Kaposi sarcoma (KS); primary effusion lymphoma (PEL), an aggressive non-Hodgkin B-cell lymphoma; a plasmablastic variant of multicentric Castleman disease (MCD); and KSHV inflammatory cytokine syndrome (KICS), a systemic…

681 – Proteomic Profiling Identifies CLPP Associated With InSTI-Induced Weight Gain in People With HIV

Background The use of integrase strand transfer inhibitors (INSTI) is associated with weight gain, but the underlying mechanisms remain unclear. This study aims to compare the plasma proteomic alterations in people with HIV (PWH) who experienced different weight trends after using INSTI, and to identify critical factors in INSTI-induced weight gain. Methods Three cohorts of…

692 – Glucose and Insulin Metabolism in Middle-Aged Women With Comorbid HIV and Obesity in South Africa

Background The interplay between HIV, antiretroviral therapy (ART) and adiposity impacts glucose homeostasis in ways that remain incompletely understood.  Methods Middle-aged South African women with (WWH) and without HIV (WoH) not taking diabetes medications completed anthropometry, dual-energy X-ray absorptiometry and oral glucose tolerance testing. We estimated glucose area under the curve (AUC), homeostatic model assessment-2…

234 – Extended-Release Naltrexone Attenuates Inflammatory Signatures in PWH With Opioid Use Disorder

Background Chronic opioid use among people with HIV (PWH) remains an ongoing public health crisis. The interaction between opioids and HIV may exacerbate HIV-associated immune dysregulation and chronic inflammation, increasing the risk of both AIDS-related and non-AIDS-related morbidity and mortality. Treatment for opioid use disorder (OUD) includes opioid agonists such as buprenorphine or methadone, commonly…

261 – Plasma Metabolomics Uncover Multiple Dysregulations Indicating Gut Damage in SIV-Infected Macaques

Background Despite effective antiretroviral therapies (ART), people living with HIV (PWH) have elevated rates of inflammation, hypercoagulation, and associated comorbidities. Gut damage correlates with immune dysfunction in PWH, but precise etiologies remain poorly defined. Due to heterogeneity of clinical cohorts, generalizable metabolomic studies from PWH are limited but can be augmented with animal models. Methods…

263 – Productive HIV-1 Infection in CRISPR CD4/CCR5/C1qbp Knock-In CD8-Depleted Mice

Background Rodents cannot be infected with HIV due to multiple obstacles. First, HIV requires human CD4/CCR5/CXCR4 on human immunocytes, each are structured differently in mice. Second, post-transcriptional factors absent in rodent cells limit viral RNA export, translation, stability, viral assembly, and release.  Third, rodent CD8+ T-cell viral control is active in rodents with active killing of…